The Immunopathologic Effects of Mycoplasma pneumoniae and Community-acquired Respiratory Distress Syndrome Toxin. A

Diego J Maselli1, Jorge L Medina2,3, Edward G Brooks3,4

  • 11 Division of Pulmonary Diseases and Critical Care Medicine, Department of Medicine.

Insights

Mycoplasma pneumoniae and its CARDS toxin cause asthma-like lung changes in primates. The toxin is a key driver of airway inflammation and dysfunction, impacting asthma outcomes.

Area of Science:

  • Pulmonary immunology
  • Microbial pathogenesis

Background:

  • Mycoplasma pneumoniae infection is associated with adverse asthma outcomes.
  • The bacterium produces the community-acquired respiratory distress syndrome (CARDS) toxin, implicated in airway inflammation and dysfunction.

Purpose of the Study:

  • To investigate the immunopathological effects of M. pneumoniae and CARDS toxin exposure in a primate model.
  • To evaluate the role of CARDS toxin in mediating inflammation and airway changes.

Main Methods:

  • 13 baboons were exposed to M. pneumoniae or CARDS toxin.
  • Bronchoalveolar lavage (BAL) fluid and serum were analyzed for cellular, molecular, and serological markers.
  • Pulmonary histopathology was assessed post-necropsy.

Main Results:

  • Histological "asthma-like" changes were observed in animals exposed to M. pneumoniae and CARDS toxin by Day 14.
  • An increased IL-4/IFN-γ ratio was noted in T cells over time.
  • CARDS toxin exposure alone induced pulmonary changes similar to those seen with M. pneumoniae infection.

Conclusions:

  • CARDS toxin plays a significant role in the pulmonary inflammatory response associated with M. pneumoniae infection.
  • The findings suggest CARDS toxin as a potential therapeutic target for mitigating M. pneumoniae-induced airway dysfunction.